Abstract. Twelve patients, six women and six men, with macroprolactinomas characterized by extrasellar extension and basal plasma prolactin levels >6 U/l were treated with 10\p=n-\20 mg bromocriptine daily in four divided doses for a mean period of 2.4 years (range 0.5\p=n-\3.5 years). The 
or medical therapy with dopa¬ mine agonists particularly bromocriptine (Gross¬ man & Besser 1985) . In prolactin secreting macroadenomas surgical cure rate diminishes with increasing tumour size and prolactin level (Randall et al. 1983 ). Medical therapy with bro¬ mocriptine has been found to shrink most macro¬ prolactinomas concomitant with a decrease of plasma prolactin levels (Vance et al. 1984) . In a recent multicenter study Molitch et al. (1985) present a systematic evaluation of the effective¬ ness of bromocriptine as primary therapy for macroprolactinomas in a group of 27 patients followed for a period of 6-15 months. The pre¬ sent study describes the results of a similar study from one center using a fixed dose of bromocrip¬ tine in 12 patients who have been followed-up for a mean period of 2.4 years.
Patients and Methods
Patients and experimental protocol 
Results

Prolactin levels
Basal plasma prolactin levels ranged from 7 to 210 U/l (Table 1 ). In seven patients younger than 50 years plasma prolactin levels ranged from 7 to 43 U/I, whereas in the five patients between 50 and 60 years plasma prolactin levels ranged from 80 to 210 U/l. (Fig. 1) . In all patients except No. 4, who had a hypodense tumour from the beginning, the tu¬ mours became more hypodense on CT scans per¬ formed during treatment (Fig. 1) (Schlezinger & Thompson 1967) .
In agreement with the findings of previous studies (Prescott et (Aubourg et al. 1980; Rawe et al. 1980; Faria & Tindall 1982) .
From our data it is suggested that a fixed schedule of bromocriptine of at least 10 mg daily given in four divided doses is superior to a sched¬ ule based on the plasma prolactin lowering effect of bromocriptine.
To continue bromocriptine therapy indefinitely once a major tumour shrinkage has occurred and hormonal function is normalized seems an accept¬ able approach at present.
